ATE292187T1 - Verfahren und zusammensetzungen für die abgabe von pharmazeutischen wirkstoffen - Google Patents

Verfahren und zusammensetzungen für die abgabe von pharmazeutischen wirkstoffen

Info

Publication number
ATE292187T1
ATE292187T1 AT00961303T AT00961303T ATE292187T1 AT E292187 T1 ATE292187 T1 AT E292187T1 AT 00961303 T AT00961303 T AT 00961303T AT 00961303 T AT00961303 T AT 00961303T AT E292187 T1 ATE292187 T1 AT E292187T1
Authority
AT
Austria
Prior art keywords
methods
compositions
cationic
cells
solubilized
Prior art date
Application number
AT00961303T
Other languages
English (en)
Inventor
Kesavan Esuvaranathan
Ratha Mahendran
Carmel Lawrencia
Original Assignee
Genecure Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genecure Pte Ltd filed Critical Genecure Pte Ltd
Application granted granted Critical
Publication of ATE292187T1 publication Critical patent/ATE292187T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
AT00961303T 1999-09-01 2000-09-01 Verfahren und zusammensetzungen für die abgabe von pharmazeutischen wirkstoffen ATE292187T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ2593A AUPQ259399A0 (en) 1999-09-01 1999-09-01 Therapeutic agents
PCT/SG2000/000130 WO2001015755A2 (en) 1999-09-01 2000-09-01 Methods and compositions for delivery of pharmaceutical agents

Publications (1)

Publication Number Publication Date
ATE292187T1 true ATE292187T1 (de) 2005-04-15

Family

ID=3816764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961303T ATE292187T1 (de) 1999-09-01 2000-09-01 Verfahren und zusammensetzungen für die abgabe von pharmazeutischen wirkstoffen

Country Status (11)

Country Link
US (2) US7320963B2 (de)
EP (1) EP1208218B1 (de)
JP (1) JP4995388B2 (de)
AT (1) ATE292187T1 (de)
AU (2) AUPQ259399A0 (de)
CA (1) CA2384425C (de)
DE (1) DE60019134T2 (de)
ES (1) ES2240157T3 (de)
NO (1) NO329773B1 (de)
TW (1) TWI262085B (de)
WO (1) WO2001015755A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ259399A0 (en) * 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
EP1233671A4 (de) * 1999-11-29 2005-11-02 Mirus Corp Zusammensetzungen und verfahren zur arzneistoffabgabe unter verwendung von amphiphilen bindungsmolekülen
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US7153905B2 (en) * 2003-03-21 2006-12-26 The General Hospital Corporation Hyperbranched dendron and methods of synthesis and use thereof
US8545830B2 (en) * 2003-03-24 2013-10-01 University Of Tennessee Research Foundation Multi-functional polymeric materials and their uses
WO2005007850A1 (ja) * 2003-07-16 2005-01-27 Kumamoto Technology & Industry Foundation 細胞にｒｎａを導入する方法
PL1789534T3 (pl) 2004-08-16 2015-03-31 Cellresearch Corp Pte Ltd Wyodrębnienie komórek macierzystych/progenitorowych z błony owodniowej pępowiny
WO2006130978A1 (en) 2005-06-06 2006-12-14 The University Of British Columbia Polymer-based serum albumin substitute
CN103555655B (zh) 2005-10-21 2018-02-27 细胞研究私人有限公司 自脐带羊膜分离和培养干/祖细胞及其分化的细胞的应用
ITMI20071173A1 (it) * 2007-06-11 2008-12-12 Univ Degli Studi Milano Polimeri iperramificati a base di ciclodestrine e poli(amidoammine) per il rilascio controllato di farmaci insolubili
BR112012021991A2 (pt) 2010-03-01 2020-09-01 The University Of British Columbia policlicerol hiperramificado uso de um poliglicerol hipermanificado, método de adiministração de uma força biologicamente ativa a um tecido biológico, composição farmacêutica e método de síntese de um poliglicerol hiperrramificado.
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
WO2013074526A2 (en) 2011-11-15 2013-05-23 Byocoat Enterprises, Inc. Antimicrobial compositions and methods of use thereof
WO2014025795A1 (en) 2012-08-07 2014-02-13 Northeastern University Compositions for the delivery of rna and drugs into cells
CN105764913B (zh) * 2013-06-21 2019-03-05 加图立大学校产学协力团 用于药物输送的还原性或非还原性多核苷酸聚合物及其制备方法
EP3122872B1 (de) 2014-03-27 2019-07-03 The Salk Institute for Biological Studies Zusammensetzungen und verfahren zur behandlung von typ-1-diabetes und typ-2-diabetes sowie von verwandten erkrankungen
AU2016225076B2 (en) 2015-02-27 2018-09-13 Salk Institute For Biological Studies Reprogramming progenitor compositions and methods of use therefore
US11760977B2 (en) 2016-05-25 2023-09-19 Salk Institute For Biological Studies Compositions and methods for organoid generation and disease modeling
CN106924746B (zh) * 2017-03-03 2020-11-03 中山大学 复合基因载体及其应用
EP3723806A1 (de) 2017-12-11 2020-10-21 Fondazione Istituto Firc Di Oncologia Molecolare (IFOM) Polycomb-inhibitoren und verwendungen davon
EP3924521A4 (de) 2019-02-15 2023-03-29 IncellDx, Inc. Test von blasenassoziierten proben, identifizierung und behandlung von blasenassoziierter neoplasie und kits zur verwendung darin
CN113181119B (zh) * 2021-05-08 2023-08-29 深圳市第二人民医院(深圳市转化医学研究院) 载药系统及其制备方法、药物组合物
CN113082001B (zh) * 2021-05-25 2023-05-26 中国科学院广州生物医药与健康研究院 一种核酸递送系统及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
US5614503A (en) * 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
US5691316A (en) * 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
CA2220950A1 (en) 1995-05-26 1996-11-28 Somatix Therapy Corporation Delivery vehicles comprising stable lipid/nucleic acid complexes
US5932241A (en) 1995-06-07 1999-08-03 Valentis, Incorporated Cationic lipid DNA complexes for gene targeting
US5830878A (en) 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
WO1998013026A1 (en) * 1997-06-10 1998-04-02 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US6413544B1 (en) 1996-08-19 2002-07-02 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
WO1998040499A1 (en) * 1997-03-10 1998-09-17 Heather Lynn Davis Gene delivery to mucosal epithelium for immunization or therapeutic purposes
EP0975332A1 (de) 1997-04-04 2000-02-02 Valentis Inc. Verbesserte verfahren zur verabreichung unter verwendung von kationischen lipiden und helfer-lipiden
AU7490098A (en) * 1997-05-15 1998-12-08 Genzyme Corporation Cationic amphiphile formulations
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
AU9404398A (en) 1997-09-23 1999-04-12 Megabios Corporation Methods for preparing lipids/polynucleotide transfection complexes
AUPQ259399A0 (en) * 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
CA2395636A1 (en) * 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy

Also Published As

Publication number Publication date
NO20020983L (no) 2002-04-24
WO2001015755A2 (en) 2001-03-08
AU7327500A (en) 2001-03-26
US20090054364A1 (en) 2009-02-26
CA2384425A1 (en) 2001-03-08
AUPQ259399A0 (en) 1999-09-23
US20020146830A1 (en) 2002-10-10
DE60019134D1 (de) 2005-05-04
EP1208218A2 (de) 2002-05-29
TWI262085B (en) 2006-09-21
US7320963B2 (en) 2008-01-22
DE60019134T2 (de) 2006-02-09
JP2003508456A (ja) 2003-03-04
EP1208218B1 (de) 2005-03-30
CA2384425C (en) 2011-01-25
WO2001015755A3 (en) 2002-02-28
JP4995388B2 (ja) 2012-08-08
ES2240157T3 (es) 2005-10-16
US7709457B2 (en) 2010-05-04
AU781684B2 (en) 2005-06-09
NO20020983D0 (no) 2002-02-27
NO329773B1 (no) 2010-12-13

Similar Documents

Publication Publication Date Title
ATE292187T1 (de) Verfahren und zusammensetzungen für die abgabe von pharmazeutischen wirkstoffen
Dosta et al. Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles
Hou et al. Innovations in the treatment of dystrophic epidermolysis bullosa (DEB): current landscape and prospects
Li et al. Charge-convertible polymers for improved tumor targeting and enhanced therapy
Tran et al. Modulation of macrophage functional polarity towards anti-inflammatory phenotype with plasmid DNA delivery in CD44 targeting hyaluronic acid nanoparticles
Nuhn et al. pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation
Furgeson et al. Modified linear polyethylenimine− cholesterol conjugates for DNA complexation
Nukolova et al. LHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer
Venuganti et al. Topical gene silencing by iontophoretic delivery of an antisense oligonucleotide–dendrimer nanocomplex: the proof of concept in a skin cancer mouse model
Gao et al. Injectable and photocurable gene scaffold facilitates efficient repair of spinal cord injury
DE69835692D1 (de) Geladene lipide und deren verwendung
Kim et al. Synergistic effects of hyaluronate–epidermal growth factor conjugate patch on chronic wound healing
Ma et al. Bioinspired spatiotemporal management toward RNA therapies
Hu et al. Mechanisms of hydrogel-based microRNA delivery systems and its application strategies in targeting inflammatory diseases
Ferruti et al. Prevailingly cationic agmatine-based amphoteric polyamidoamine as a nontoxic, nonhemolytic, and “stealthlike” DNA complexing agent and transfection promoter
CN1646170A (zh) 温度响应输送系统
Cavalli et al. Amphoteric agmatine containing polyamidoamines as carriers for plasmid DNA in vitro and in vivo delivery
Kim et al. Injectable hydrogel systems for local cancer therapy
Wang et al. A Metal–Organic Framework-Based Immune-Regulating Nanocarrier Depot for Enhanced Combination Cancer Immunotherapy
Zhang et al. Tumor-associated macrophages regulating a polymer nanoplatform for synergistic treatment of breast tumors
Niu et al. Silk peptide-hyaluronic acid based nanogels for the enhancement of the topical administration of curcumin
Li et al. Potential applications of ROS-responsive silk fibroin materials in smart drug delivery systems
Cui et al. Engineered microalgal extracellular vesicles for enhancing mitochondrial homeostasis in radiodermatitis prevention
Gu et al. Molecule engineering strategy of toll-like receptor 7/8 agonists designed for potentiating immune stimuli activation
Li et al. Well-defined DNA–polymer miktoarm stars for enzyme-resistant nanoflares and carrier-free gene regulation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1208218

Country of ref document: EP